Docetaxel

Generic Name
Docetaxel
Brand Names
Taxotere, Docetaxel Accord, Docetaxel Kabi
Drug Type
Small Molecule
Chemical Formula
C43H53NO14
CAS Number
114977-28-5
Unique Ingredient Identifier
699121PHCA
Background

Docetaxel is a clinically well established anti-mitotic chemotherapy medication used for the treatment of different types of cancer, including breast, ovarian, and non-small cell lung cancer. Docetaxel is a complex diterpenoid molecule and a semisynthetic analogue of paclitaxel. Docetaxel reversibly binds to microtubulin with high affinity in a 1:1 stoichiometric ratio, allowing it to prevent cell division and promote to cell death. Compared to paclitaxel, docetaxel is two times more potent as an inhibitor of microtubule depolymerization. Docetaxel binds to microtubules but does not interact with dimeric tubulin.

The use of docetaxel may lead to udesired outcomes such as hepatic impairment, hematologic effects, enterocolitis and neutropenic colitis, hypersensitivity reactions, fluid retention, second primary malignancies, embryo-fetal toxicity, and tumor lysis syndrome. Docetaxel was approved by the FDA in 1996 and is available in solution for injection for intravenous or parenteral administration.

Indication

Docetaxel is indicated as a single agent for the treatment of locally advanced or metastatic breast cancer after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC. It is also indicated as a single agent for locally advanced or metastatic non-small cell lung cancer (NSCLC) after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC. For the treatment of metastatic castration-resistant prostate cancer, docetaxel is indicated with prednisone. Docetaxel is also indicated with cisplatin and fluorouracil for untreated, advanced gastric adenocarcinoma, including the gastroesophageal junction, and with cisplatin and fluorouracil for induction treatment of locally advanced squamous cell carcinoma of the head and neck (SCCHN).

Associated Conditions
Esophageal Cancer, Ewing's Sarcoma, Locally Advanced Breast Cancer (LABC), Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Node Positive Breast Cancer, Ovarian Cancer Metastatic, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Advanced untreated gastric adenocarcinoma, Locally advanced Squamous cell carcinoma of head and neck, Locally advanced untreated non small cell lung cancer, Metastatic untreated non small cell lung cancer, Refractory, locally advanced Non small cell lung cancer, Refractory, metastatic Non small cell lung cancer, Refractory, metastatic hormone-refractory Prostate cancer
Associated Therapies
-

A Dose-finding Trial of Hyperthermic Intraperitoneal Docetaxel

First Posted Date
2022-06-08
Last Posted Date
2022-06-08
Lead Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Target Recruit Count
30
Registration Number
NCT05410483
Locations
🇨🇳

Sun Yat-sen Memorial Hospital, Guangzhou, Other (Non U.s.), China

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) for Recurrent, Metastatic, or Unresectable HER2-Positive Salivary Gland Cancer

First Posted Date
2022-06-07
Last Posted Date
2024-11-27
Lead Sponsor
NRG Oncology
Target Recruit Count
116
Registration Number
NCT05408845
Locations
🇺🇸

UCSF Medical Center-Mission Bay, San Francisco, California, United States

🇺🇸

Emory University Hospital Midtown, Atlanta, Georgia, United States

🇺🇸

University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States

and more 116 locations

Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1

First Posted Date
2022-05-20
Last Posted Date
2024-10-14
Lead Sponsor
Laekna Limited
Target Recruit Count
167
Registration Number
NCT05383482
Locations
🇨🇳

Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China

🇨🇳

Beijing Cancer Hospital, Beijing, Beijing, China

🇨🇳

Chongqing Cancer Hospital, Chongqing, Chengdu, China

and more 2 locations

A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors

First Posted Date
2022-05-19
Last Posted Date
2024-10-23
Lead Sponsor
BeiGene
Target Recruit Count
210
Registration Number
NCT05381909
Locations
🇦🇺

Icon Cancer Centre South Brisbane, South Brisbane, Queensland, Australia

🇦🇺

Peter Maccallum Cancer Centre, Melbourne, Victoria, Australia

🇺🇸

Banner Md Anderson Cancer Center, Gilbert, Arizona, United States

and more 19 locations

A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations

Phase 3
Suspended
Conditions
Interventions
First Posted Date
2022-05-18
Last Posted Date
2024-11-13
Lead Sponsor
Spectrum Pharmaceuticals, Inc
Target Recruit Count
268
Registration Number
NCT05378763
Locations
🇺🇸

Bond Clinic, P.A., Winter Haven, Florida, United States

Study of Cemiplimab - TP Induction Chemotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck

First Posted Date
2022-05-17
Last Posted Date
2024-11-18
Lead Sponsor
Krzysztof Misiukiewicz
Target Recruit Count
24
Registration Number
NCT05376553
Locations
🇺🇸

Icahn School of Medicine at Mount Sinai, New York, New York, United States

Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

Phase 3
Active, not recruiting
Conditions
Interventions
First Posted Date
2022-04-27
Last Posted Date
2024-10-07
Lead Sponsor
AstraZeneca
Target Recruit Count
1017
Registration Number
NCT05348577
Locations
🇬🇧

Research Site, Sutton, United Kingdom

IN10018 Monotherapy or in Combination With Docetaxel in Gastric or GEJ Adenocarcinoma

Phase 1
Completed
Conditions
Interventions
First Posted Date
2022-04-14
Last Posted Date
2022-11-16
Lead Sponsor
InxMed (Shanghai) Co., Ltd.
Target Recruit Count
33
Registration Number
NCT05327231
Locations
🇨🇳

Henan Cancer Hospital, Zhengzhou, Henan, China

🇨🇳

The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China

🇨🇳

Anyang Tumor Hospital, Anyang, Henan, China

and more 5 locations

Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer

First Posted Date
2022-04-11
Last Posted Date
2022-04-11
Lead Sponsor
Zhejiang Cancer Hospital
Target Recruit Count
80
Registration Number
NCT05322499
Locations
🇨🇳

Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

© Copyright 2024. All Rights Reserved by MedPath